Third dose of COVID-19 vaccine does not appear to increase severe adverse events

Investigators report that even though there was some increase in cases of low-severity adverse events after third-dose vaccination against SARS-CoV-2 infection with mRNA vaccines, such third-dose vaccination did not significantly increase severe adverse events. The findings appeared on April 14, 2022 in JAMA Network Open. As background the authors said. “Recent reports on waning of COVID-19 vaccine–induced immunity have led […]

Conventional vaccine messages miss the mark

Promotional campaigns designed to increase vaccine uptake are often ineffective, according to a new study in eight European countries. Some initiatives which highlight the benefits of immunisation may even be counterproductive, say scientists. Researchers at the Technical University of Munich worked with colleagues at the University of Trento and the London School of Economics and Political Science to test the […]

EU experts cautious on fourth dose of COVID-19

It is ‘too early’ to consider using a fourth dose of mRNA COVID-19 vaccines in the general population, according to the European Medicines Agency (EMA) and the European Centre for Disease Prevention & Control (ECDC). However, experts from both agencies agreed that a fourth dose – or second booster shot – can be given to adults 80 years of age. […]

Additional COVID vaccine helps protect transplant patients

Additional booster doses of vaccine against COVID-19 are particularly important for those who are immunosuppressed, namely those who have had solid organ transplants, a new study shows. The study, published in the Journal of Infectious Diseases, shows that even after vaccination, patients taking immunosuppressive medications to prevent rejection of an organ transplant have higher risk for severe COVID-19 than those with […]

New COVID-19 nasal spray outperforms current antibody treatments in mice

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19. Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. The top protein neutralized the […]

“Long Covid” linked to disease of small airways in lungs

Researchers report that persistent disease of the small airways in the lungs, with yet unknown long-term effects, appears to be a possible log-term effect of COVID-19, and it is unrelated to initial infection severity. The findings were published on March 15, 2022 in Radiology. “For the first time, we’re describing small airways disease in this population of COVID-19 patients with […]

Ivermectin associated with lower mortality than remdesivir

An analysis of the records more than 41,000 patients who had covid-19 and were treated with either ivermectin or remdesivir showed that ivermectin was associated with significantly lower risk of death. Researchers used data from the TriNetX Research network, a federated EMR network of over 44 healthcare organizations and 68 million patients in the US, to identify covid-19 cases. They […]

Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus – AstraZeneca

AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy. Saphnelo is the first biologic for SLE approved in Europe with an indication that is not restricted to patients with a high degree of disease activity. […]

TGA in Australia has granted provisional registration for Spikevax COVID 19 vaccine for children aged 6-11 years old – Moderna

Moderna, Inc., announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna’s mRNA COVID-19 vaccine, Spikevax, in a 50 µg dose, two-dose series, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years. The TGA authorization for the use of the COVID-19 vaccine in children 6-11 years old […]